Clinical Trials Logo

Miscarriage clinical trials

View clinical trials related to Miscarriage.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05168865 Withdrawn - Miscarriage Clinical Trials

Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients.

Start date: August 1, 2023
Phase: Phase 4
Study type: Interventional

One of the indications of freezing is to reduce the risk of ovarian hyperstimulation syndrome particularly in polycystic ovarian disease (PCOS) women. Very few RCTs addressed the issue of optimizing the endometrium for a frozen cycle. Interestingly, Letrozole for ovarian stimulation showed significantly better reproductive outcome when compared with hormone replacement therapy (HRT) cycle. In addition, HRT cycle has been associated with higher miscarriage rate when compared with natural cycle frozen embryo transfer. Nevertheless, there is not yet a well-designed prospective randomized study comparing letrozole and HRT in PCOS women undergoing frozen embryo transfer.

NCT ID: NCT02379650 Withdrawn - Miscarriage Clinical Trials

Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss

Start date: July 2016
Phase: Phase 2
Study type: Interventional

Recurrent pregnancy loss (RPL) affects 5% of couples trying to achieve parenthood. Most cases of RPL are unexplained and have no effective treatment to improve the likelihood of a pregnancy resulting in a live birth. This leads to significant patient and provider frustration and emotional stress. Hydroxychloroquine (HCQ) is a medication commonly used in pregnancy to treat autoimmune and connective tissue diseases such as systemic lupus erythematosus (SLE). This use has shown that HCQ is very safe in pregnancy. HCQ has anti-inflammatory and anti-thrombotic effects and thus may improve pregnancy outcomes in couples with unexplained RPL. Although some providers are already prescribing HCQ for unexplained RPL, a randomized controlled trial is necessary to determine the true efficacy and safety of this treatment. This study has the potential to establish support for a new treatment option for unexplained RPL.